APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI Pharma

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global AI Pharma Market Outlook and Growth Opportunities 2026

2 January 2026212 pages

Choose your research edition.

Industry ResearchAI Pharma Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal AI Pharma Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal AI Pharma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI Pharma Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal AI Pharma Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global AI Pharma market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for AI Pharma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AI Pharma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AI Pharma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the AI Pharma market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the AI Pharma market include Recursion, Insilico Medicine, Exscientia, BenevolentAI, Atomwise, Roivant Sciences, Schrödinger, Lantern Pharma and XtalPi, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global AI Pharma market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AI Pharma and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AI Pharma revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global AI Pharma market.

AI Pharma Segment by Company

Recursion

Insilico Medicine

Exscientia

BenevolentAI

Atomwise

Roivant Sciences

Schrödinger

Lantern Pharma

XtalPi

Landos Biopharma

Relay Therapeutics

Accutar Biotech

Deep Genomics

Oncocross

AI Therapeutics

BioMap

METiS Pharmaceuticals

NeoX Biotech

StoneWise

Deep Intelligent Pharma

Gigaceuticals

Chemical.AI

Artivila

Galixir

Xbiome

AI Pharma Segment by Type

Self-developed Oipeline

Contract Research Organization (CRO)

Other

AI Pharma Segment by Application

Preclinical Stage (Optimization of Lead Compounds, etc.)

Clinical Trial Phase (Predicting Treatment Outcome, etc.)

AI Pharma Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global AI Pharma status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the AI Pharma key companies, revenue, market share, and recent developments.

3. To split the AI Pharma breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions AI Pharma market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify AI Pharma significant trends, drivers, influence factors in global and regions.

6. To analyze AI Pharma competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Pharma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI Pharma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Pharma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI Pharma industry.

Chapter 3: Detailed analysis of AI Pharma company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of AI Pharma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of AI Pharma in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. AI Pharma Industry Trends Table 2. AI Pharma Industry Drivers Table 3. AI Pharma Industry Opportunities and Challenges Table 4. AI Pharma Industry Restraints Table 5. Global AI Pharma Revenue by Company (US$ Million) & (2021-2026) Table 6. Global AI Pharma Revenue Share by Company (2021-2026) Table 7. Global AI Pharma Company Ranking, (2024-2026) & (US$ Million) Table 8. Global AI Pharma Key Company Manufacturing Base & Headquarters Table 9. Global AI Pharma Company, Product Type & Application Table 10. Global AI Pharma Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global AI Pharma by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Self-developed Oipeline Table 15. Significant Companies of Contract Research Organization (CRO) Table 16. Significant Companies of Other Table 17. Global AI Pharma Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global AI Pharma Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global AI Pharma Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global AI Pharma Sales Value Share by Type (2021-2026) Table 21. Global AI Pharma Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Preclinical Stage (Optimization of Lead Compounds, etc.) Table 23. Significant Companies of Clinical Trial Phase (Predicting Treatment Outcome, etc.) Table 24. Global AI Pharma Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global AI Pharma Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global AI Pharma Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global AI Pharma Sales Value Share by Application (2021-2026) Table 28. Global AI Pharma Sales Value Share by Application (2027-2032) Table 29. Global AI Pharma Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global AI Pharma Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global AI Pharma Sales Value Share by Region (2021-2026) Table 32. Global AI Pharma Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global AI Pharma Sales Value Share by Region (2027-2032) Table 34. Global AI Pharma Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global AI Pharma Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global AI Pharma Sales Value Market Share by Country (2021-2026) Table 37. Global AI Pharma Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global AI Pharma Sales Value Market Share by Country (2027-2032) Table 39. Recursion Company Information Table 40. Recursion Business Overview Table 41. Recursion AI Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Recursion AI Pharma Product Portfolio Table 43. Recursion Recent Development Table 44. Insilico Medicine Company Information Table 45. Insilico Medicine Business Overview Table 46. Insilico Medicine AI Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Insilico Medicine AI Pharma Product Portfolio Table 48. Insilico Medicine Recent Development Table 49. Exscientia Company Information Table 50. Exscientia Business Overview Table 51. Exscientia AI Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Exscientia AI Pharma Product Portfolio Table 53. Exscientia Recent Development Table 54. BenevolentAI Company Information Table 55. BenevolentAI Business Overview Table 56. BenevolentAI AI Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. BenevolentAI AI Pharma Product Portfolio Table 58. BenevolentAI Recent Development Table 59. Atomwise Company Information Table 60. Atomwise Business Overview Table 61. Atomwise AI Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Atomwise AI Pharma Product Portfolio Table 63. Atomwise Recent Development Table 64. Roivant Sciences Company Information Table 65. Roivant Sciences Business Overview Table 66. Roivant Sciences AI Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Roivant Sciences AI Pharma Product Portfolio Table 68. Roivant Sciences Recent Development Table 69. Schrödinger Company Information Table 70. Schrödinger Business Overview Table 71. Schrödinger AI Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Schrödinger AI Pharma Product Portfolio Table 73. Schrödinger Recent Development Table 74. Lantern Pharma Company Information Table 75. Lantern Pharma Business Overview Table 76. Lantern Pharma AI Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Lantern Pharma AI Pharma Product Portfolio Table 78. Lantern Pharma Recent Development Table 79. XtalPi Company Information Table 80. XtalPi Business Overview Table 81. XtalPi AI Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. XtalPi AI Pharma Product Portfolio Table 83. XtalPi Recent Development Table 84. Landos Biopharma Company Information Table 85. Landos Biopharma Business Overview Table 86. Landos Biopharma AI Pharma Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Landos Biopharma AI Pharma Product Portfolio Table 88. Landos Biopharma Recent Development Table 89. Relay Therapeutics Company Information Table 90. Relay Therapeutics Business Overview Table 91. Relay Therapeutics AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Relay Therapeutics AI Pharma Product Portfolio Table 93. Relay Therapeutics Recent Development Table 94. Accutar Biotech Company Information Table 95. Accutar Biotech Business Overview Table 96. Accutar Biotech AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Accutar Biotech AI Pharma Product Portfolio Table 98. Accutar Biotech Recent Development Table 99. Deep Genomics Company Information Table 100. Deep Genomics Business Overview Table 101. Deep Genomics AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Deep Genomics AI Pharma Product Portfolio Table 103. Deep Genomics Recent Development Table 104. Oncocross Company Information Table 105. Oncocross Business Overview Table 106. Oncocross AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Oncocross AI Pharma Product Portfolio Table 108. Oncocross Recent Development Table 109. AI Therapeutics Company Information Table 110. AI Therapeutics Business Overview Table 111. AI Therapeutics AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. AI Therapeutics AI Pharma Product Portfolio Table 113. AI Therapeutics Recent Development Table 114. BioMap Company Information Table 115. BioMap Business Overview Table 116. BioMap AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. BioMap AI Pharma Product Portfolio Table 118. BioMap Recent Development Table 119. METiS Pharmaceuticals Company Information Table 120. METiS Pharmaceuticals Business Overview Table 121. METiS Pharmaceuticals AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. METiS Pharmaceuticals AI Pharma Product Portfolio Table 123. METiS Pharmaceuticals Recent Development Table 124. NeoX Biotech Company Information Table 125. NeoX Biotech Business Overview Table 126. NeoX Biotech AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. NeoX Biotech AI Pharma Product Portfolio Table 128. NeoX Biotech Recent Development Table 129. StoneWise Company Information Table 130. StoneWise Business Overview Table 131. StoneWise AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. StoneWise AI Pharma Product Portfolio Table 133. StoneWise Recent Development Table 134. Deep Intelligent Pharma Company Information Table 135. Deep Intelligent Pharma Business Overview Table 136. Deep Intelligent Pharma AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Deep Intelligent Pharma AI Pharma Product Portfolio Table 138. Deep Intelligent Pharma Recent Development Table 139. Gigaceuticals Company Information Table 140. Gigaceuticals Business Overview Table 141. Gigaceuticals AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Gigaceuticals AI Pharma Product Portfolio Table 143. Gigaceuticals Recent Development Table 144. Chemical.AI Company Information Table 145. Chemical.AI Business Overview Table 146. Chemical.AI AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Chemical.AI AI Pharma Product Portfolio Table 148. Chemical.AI Recent Development Table 149. Artivila Company Information Table 150. Artivila Business Overview Table 151. Artivila AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Artivila AI Pharma Product Portfolio Table 153. Artivila Recent Development Table 154. Galixir Company Information Table 155. Galixir Business Overview Table 156. Galixir AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Galixir AI Pharma Product Portfolio Table 158. Galixir Recent Development Table 159. Xbiome Company Information Table 160. Xbiome Business Overview Table 161. Xbiome AI Pharma Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Xbiome AI Pharma Product Portfolio Table 163. Xbiome Recent Development Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. AI Pharma Product Image Figure 2. Global AI Pharma Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI Pharma Market Size (2021-2032) & (US$ Million) Figure 4. Global AI Pharma Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Self-developed Oipeline Image Figure 8. Contract Research Organization (CRO) Image Figure 9. Other Image Figure 10. Global AI Pharma Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global AI Pharma Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global AI Pharma Sales Value Share by Type (2021-2032) Figure 13. Preclinical Stage (Optimization of Lead Compounds, etc.) Image Figure 14. Clinical Trial Phase (Predicting Treatment Outcome, etc.) Image Figure 15. Global AI Pharma Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global AI Pharma Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global AI Pharma Sales Value Share by Application (2021-2032) Figure 18. Global AI Pharma Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global AI Pharma Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America AI Pharma Sales Value (2021-2032) & (US$ Million) Figure 21. North America AI Pharma Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe AI Pharma Sales Value (2021-2032) & (US$ Million) Figure 23. Europe AI Pharma Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific AI Pharma Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific AI Pharma Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America AI Pharma Sales Value (2021-2032) & (US$ Million) Figure 27. South America AI Pharma Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa AI Pharma Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa AI Pharma Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt AI Pharma Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt AI Pharma Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt AI Pharma Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Self-developed Oipeline
  • Contract Research Organization (CRO)
  • Other
Applications
  • Preclinical Stage (Optimization of Lead Compounds, etc.)
  • Clinical Trial Phase (Predicting Treatment Outcome, etc.)
Companies covered
  • Recursion
  • Insilico Medicine
  • Exscientia
  • BenevolentAI
  • Atomwise
  • Roivant Sciences
  • Schrödinger
  • Lantern Pharma
  • XtalPi
  • Landos Biopharma
  • Relay Therapeutics
  • Accutar Biotech
  • Deep Genomics
  • Oncocross
  • AI Therapeutics
  • BioMap
  • METiS Pharmaceuticals
  • NeoX Biotech
  • StoneWise
  • Deep Intelligent Pharma
  • Gigaceuticals
  • Chemical.AI
  • Artivila
  • Galixir
  • Xbiome

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global AI Pharma Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global AI Pharma Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 AI Pharma Market Dynamics
  1. 2.1 AI Pharma Industry Trends
  2. 2.2 AI Pharma Industry Drivers
  3. 2.3 AI Pharma Industry Opportunities and Challenges
  4. 2.4 AI Pharma Industry Restraints
3 AI Pharma Market by Company
  1. 3.1 Global AI Pharma Company Revenue Ranking in 2025
  2. 3.2 Global AI Pharma Revenue by Company (2021-2026)
  3. 3.3 Global AI Pharma Company Ranking (2024-2026)
  4. 3.4 Global AI Pharma Company Manufacturing Base and Headquarters
  5. 3.5 Global AI Pharma Company Product Type and Application
  6. 3.6 Global AI Pharma Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global AI Pharma Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 AI Pharma Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 AI Pharma Market by Type
  1. 4.1 AI Pharma Type Introduction
  2. 4.1.1 Self-developed Oipeline
  3. 4.1.2 Contract Research Organization (CRO)
  4. 4.1.3 Other
  5. 4.2 Global AI Pharma Sales Value by Type
  6. 4.2.1 Global AI Pharma Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global AI Pharma Sales Value by Type (2021-2032)
  8. 4.2.3 Global AI Pharma Sales Value Share by Type (2021-2032)
5 AI Pharma Market by Application
  1. 5.1 AI Pharma Application Introduction
  2. 5.1.1 Preclinical Stage (Optimization of Lead Compounds, etc.)
  3. 5.1.2 Clinical Trial Phase (Predicting Treatment Outcome, etc.)
  4. 5.2 Global AI Pharma Sales Value by Application
  5. 5.2.1 Global AI Pharma Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global AI Pharma Sales Value by Application (2021-2032)
  7. 5.2.3 Global AI Pharma Sales Value Share by Application (2021-2032)
6 AI Pharma Regional Value Analysis
  1. 6.1 Global AI Pharma Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AI Pharma Sales Value by Region (2021-2032)
  3. 6.2.1 Global AI Pharma Sales Value by Region: 2021-2026
  4. 6.2.2 Global AI Pharma Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America AI Pharma Sales Value (2021-2032)
  7. 6.3.2 North America AI Pharma Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe AI Pharma Sales Value (2021-2032)
  10. 6.4.2 Europe AI Pharma Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific AI Pharma Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific AI Pharma Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America AI Pharma Sales Value (2021-2032)
  16. 6.6.2 South America AI Pharma Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa AI Pharma Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa AI Pharma Sales Value Share by Country, 2025 VS 2032
7 AI Pharma Country-level Value Analysis
  1. 7.1 Global AI Pharma Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global AI Pharma Sales Value by Country (2021-2032)
  3. 7.2.1 Global AI Pharma Sales Value by Country (2021-2026)
  4. 7.2.2 Global AI Pharma Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA AI Pharma Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA AI Pharma Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA AI Pharma Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada AI Pharma Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada AI Pharma Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada AI Pharma Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico AI Pharma Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico AI Pharma Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico AI Pharma Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany AI Pharma Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany AI Pharma Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany AI Pharma Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France AI Pharma Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France AI Pharma Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France AI Pharma Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. AI Pharma Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. AI Pharma Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. AI Pharma Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy AI Pharma Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy AI Pharma Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy AI Pharma Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain AI Pharma Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain AI Pharma Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain AI Pharma Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia AI Pharma Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia AI Pharma Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia AI Pharma Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands AI Pharma Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands AI Pharma Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands AI Pharma Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries AI Pharma Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries AI Pharma Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries AI Pharma Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China AI Pharma Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China AI Pharma Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China AI Pharma Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan AI Pharma Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan AI Pharma Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan AI Pharma Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea AI Pharma Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea AI Pharma Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea AI Pharma Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India AI Pharma Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India AI Pharma Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India AI Pharma Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia AI Pharma Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia AI Pharma Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia AI Pharma Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia AI Pharma Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia AI Pharma Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia AI Pharma Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil AI Pharma Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil AI Pharma Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil AI Pharma Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina AI Pharma Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina AI Pharma Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina AI Pharma Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile AI Pharma Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile AI Pharma Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile AI Pharma Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia AI Pharma Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia AI Pharma Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia AI Pharma Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru AI Pharma Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru AI Pharma Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru AI Pharma Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia AI Pharma Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia AI Pharma Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia AI Pharma Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel AI Pharma Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel AI Pharma Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel AI Pharma Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE AI Pharma Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE AI Pharma Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE AI Pharma Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey AI Pharma Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey AI Pharma Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey AI Pharma Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran AI Pharma Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran AI Pharma Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran AI Pharma Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt AI Pharma Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt AI Pharma Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt AI Pharma Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Recursion
  2. 8.1.1 Recursion Company Information
  3. 8.1.2 Recursion Business Overview
  4. 8.1.3 Recursion AI Pharma Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Recursion AI Pharma Product Portfolio
  6. 8.1.5 Recursion Recent Developments
  7. 8.2 Insilico Medicine
  8. 8.2.1 Insilico Medicine Company Information
  9. 8.2.2 Insilico Medicine Business Overview
  10. 8.2.3 Insilico Medicine AI Pharma Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Insilico Medicine AI Pharma Product Portfolio
  12. 8.2.5 Insilico Medicine Recent Developments
  13. 8.3 Exscientia
  14. 8.3.1 Exscientia Company Information
  15. 8.3.2 Exscientia Business Overview
  16. 8.3.3 Exscientia AI Pharma Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Exscientia AI Pharma Product Portfolio
  18. 8.3.5 Exscientia Recent Developments
  19. 8.4 BenevolentAI
  20. 8.4.1 BenevolentAI Company Information
  21. 8.4.2 BenevolentAI Business Overview
  22. 8.4.3 BenevolentAI AI Pharma Revenue and Gross Margin (2021-2026)
  23. 8.4.4 BenevolentAI AI Pharma Product Portfolio
  24. 8.4.5 BenevolentAI Recent Developments
  25. 8.5 Atomwise
  26. 8.5.1 Atomwise Company Information
  27. 8.5.2 Atomwise Business Overview
  28. 8.5.3 Atomwise AI Pharma Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Atomwise AI Pharma Product Portfolio
  30. 8.5.5 Atomwise Recent Developments
  31. 8.6 Roivant Sciences
  32. 8.6.1 Roivant Sciences Company Information
  33. 8.6.2 Roivant Sciences Business Overview
  34. 8.6.3 Roivant Sciences AI Pharma Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roivant Sciences AI Pharma Product Portfolio
  36. 8.6.5 Roivant Sciences Recent Developments
  37. 8.7 Schrödinger
  38. 8.7.1 Schrödinger Company Information
  39. 8.7.2 Schrödinger Business Overview
  40. 8.7.3 Schrödinger AI Pharma Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Schrödinger AI Pharma Product Portfolio
  42. 8.7.5 Schrödinger Recent Developments
  43. 8.8 Lantern Pharma
  44. 8.8.1 Lantern Pharma Company Information
  45. 8.8.2 Lantern Pharma Business Overview
  46. 8.8.3 Lantern Pharma AI Pharma Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lantern Pharma AI Pharma Product Portfolio
  48. 8.8.5 Lantern Pharma Recent Developments
  49. 8.9 XtalPi
  50. 8.9.1 XtalPi Company Information
  51. 8.9.2 XtalPi Business Overview
  52. 8.9.3 XtalPi AI Pharma Revenue and Gross Margin (2021-2026)
  53. 8.9.4 XtalPi AI Pharma Product Portfolio
  54. 8.9.5 XtalPi Recent Developments
  55. 8.10 Landos Biopharma
  56. 8.10.1 Landos Biopharma Company Information
  57. 8.10.2 Landos Biopharma Business Overview
  58. 8.10.3 Landos Biopharma AI Pharma Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Landos Biopharma AI Pharma Product Portfolio
  60. 8.10.5 Landos Biopharma Recent Developments
  61. 8.11 Relay Therapeutics
  62. 8.11.1 Relay Therapeutics Company Information
  63. 8.11.2 Relay Therapeutics Business Overview
  64. 8.11.3 Relay Therapeutics AI Pharma Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Relay Therapeutics AI Pharma Product Portfolio
  66. 8.11.5 Relay Therapeutics Recent Developments
  67. 8.12 Accutar Biotech
  68. 8.12.1 Accutar Biotech Company Information
  69. 8.12.2 Accutar Biotech Business Overview
  70. 8.12.3 Accutar Biotech AI Pharma Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Accutar Biotech AI Pharma Product Portfolio
  72. 8.12.5 Accutar Biotech Recent Developments
  73. 8.13 Deep Genomics
  74. 8.13.1 Deep Genomics Company Information
  75. 8.13.2 Deep Genomics Business Overview
  76. 8.13.3 Deep Genomics AI Pharma Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Deep Genomics AI Pharma Product Portfolio
  78. 8.13.5 Deep Genomics Recent Developments
  79. 8.14 Oncocross
  80. 8.14.1 Oncocross Company Information
  81. 8.14.2 Oncocross Business Overview
  82. 8.14.3 Oncocross AI Pharma Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Oncocross AI Pharma Product Portfolio
  84. 8.14.5 Oncocross Recent Developments
  85. 8.15 AI Therapeutics
  86. 8.15.1 AI Therapeutics Company Information
  87. 8.15.2 AI Therapeutics Business Overview
  88. 8.15.3 AI Therapeutics AI Pharma Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AI Therapeutics AI Pharma Product Portfolio
  90. 8.15.5 AI Therapeutics Recent Developments
  91. 8.16 BioMap
  92. 8.16.1 BioMap Company Information
  93. 8.16.2 BioMap Business Overview
  94. 8.16.3 BioMap AI Pharma Revenue and Gross Margin (2021-2026)
  95. 8.16.4 BioMap AI Pharma Product Portfolio
  96. 8.16.5 BioMap Recent Developments
  97. 8.17 METiS Pharmaceuticals
  98. 8.17.1 METiS Pharmaceuticals Company Information
  99. 8.17.2 METiS Pharmaceuticals Business Overview
  100. 8.17.3 METiS Pharmaceuticals AI Pharma Revenue and Gross Margin (2021-2026)
  101. 8.17.4 METiS Pharmaceuticals AI Pharma Product Portfolio
  102. 8.17.5 METiS Pharmaceuticals Recent Developments
  103. 8.18 NeoX Biotech
  104. 8.18.1 NeoX Biotech Company Information
  105. 8.18.2 NeoX Biotech Business Overview
  106. 8.18.3 NeoX Biotech AI Pharma Revenue and Gross Margin (2021-2026)
  107. 8.18.4 NeoX Biotech AI Pharma Product Portfolio
  108. 8.18.5 NeoX Biotech Recent Developments
  109. 8.19 StoneWise
  110. 8.19.1 StoneWise Company Information
  111. 8.19.2 StoneWise Business Overview
  112. 8.19.3 StoneWise AI Pharma Revenue and Gross Margin (2021-2026)
  113. 8.19.4 StoneWise AI Pharma Product Portfolio
  114. 8.19.5 StoneWise Recent Developments
  115. 8.20 Deep Intelligent Pharma
  116. 8.20.1 Deep Intelligent Pharma Company Information
  117. 8.20.2 Deep Intelligent Pharma Business Overview
  118. 8.20.3 Deep Intelligent Pharma AI Pharma Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Deep Intelligent Pharma AI Pharma Product Portfolio
  120. 8.20.5 Deep Intelligent Pharma Recent Developments
  121. 8.21 Gigaceuticals
  122. 8.21.1 Gigaceuticals Company Information
  123. 8.21.2 Gigaceuticals Business Overview
  124. 8.21.3 Gigaceuticals AI Pharma Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Gigaceuticals AI Pharma Product Portfolio
  126. 8.21.5 Gigaceuticals Recent Developments
  127. 8.22 Chemical.AI
  128. 8.22.1 Chemical.AI Company Information
  129. 8.22.2 Chemical.AI Business Overview
  130. 8.22.3 Chemical.AI AI Pharma Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Chemical.AI AI Pharma Product Portfolio
  132. 8.22.5 Chemical.AI Recent Developments
  133. 8.23 Artivila
  134. 8.23.1 Artivila Company Information
  135. 8.23.2 Artivila Business Overview
  136. 8.23.3 Artivila AI Pharma Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Artivila AI Pharma Product Portfolio
  138. 8.23.5 Artivila Recent Developments
  139. 8.24 Galixir
  140. 8.24.1 Galixir Company Information
  141. 8.24.2 Galixir Business Overview
  142. 8.24.3 Galixir AI Pharma Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Galixir AI Pharma Product Portfolio
  144. 8.24.5 Galixir Recent Developments
  145. 8.25 Xbiome
  146. 8.25.1 Xbiome Company Information
  147. 8.25.2 Xbiome Business Overview
  148. 8.25.3 Xbiome AI Pharma Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Xbiome AI Pharma Product Portfolio
  150. 8.25.5 Xbiome Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst